NMN
Also known as: Nicotinamide Mononucleotide · β-NMN
NMN is an oral nicotinamide-adenine-dinucleotide precursor. Sinclair-popularized longevity intervention with real Phase 2 human-trial data on insulin sensitivity. Different from injectable NAD+ in mechanism, evidence base, and accessibility.
Last reviewed · Panya.health editorial
Panya scores vendors against an 11-signal rubric. Vendors at or above 70 out of 100 are routable; below 70 are documented but get no Panya affiliate link. For prescription peptides like Mounjaro and Wegovy, Panya routes today through licensed clinicians. For research peptides like NMN, vendor scorecards land in a follow-up sprint after legal review and payment processor selection. Until then, the page surfaces commonly-mentioned vendor names so adults can do their own diligence. We do not yet earn commission on any NMN vendor.
Not medical advice. NMN is not approved for human medical use in most jurisdictions. The data below is what users do; it is not what regulators have validated. You decide your risk profile.
What it does, and how
Nicotinamide mononucleotide is a direct precursor in the NAD+ salvage pathway. Oral NMN is absorbed in the small intestine, partially converted to nicotinamide riboside (NR) by gut enzymes, then enters cells and is reconstituted to NAD+ via the NAMPT-mediated salvage step. This pathway is what cells already use to maintain NAD+ levels; supplementation theoretically supports it when intracellular NAD+ has declined with age. Yoshino 2021 in Science (sometimes cited as NEJM by mistake; the trial was published in Science) showed 250 mg/day NMN over 10 weeks in prediabetic postmenopausal women raised muscle insulin sensitivity by 25 percent. Other small trials (Igarashi 2022, Yamauchi 2023) showed mixed effects on grip strength, walking speed, and serum NAD+ levels. The bench science separates oral NMN from injectable NAD+ pharmacokinetically: most of an injected NAD+ dose is metabolized to nicotinamide before reaching cells, then converted via the same salvage pathway oral NMN feeds. From a purely-bioavailability angle, oral NMN at 250-500 mg/day has stronger pharmacokinetic support than IV NAD+ for raising intracellular NAD+ levels.
Typical practice
Community practice runs 250 to 1000 mg per day, oral, often morning on an empty stomach (though absorption is decent regardless of food state). Sublingual NMN lozenges are sold but the bioavailability advantage over capsules is not well-established. Sinclair's published self-reported regimen is 1 gram daily. The Yoshino 2021 trial dose was 250 mg, which is at the low end of community practice; most users dose 2 to 4x that. The 1 gram daily dose has not been formally trialed for safety beyond ~12 weeks. Cycling is debated; Sinclair takes it continuously, the longevity-physician community is split. Stacking with resveratrol or trimethylglycine (TMG, methyl-donor) is common; TMG specifically because elevated NAD+ recycling burns through methyl groups.
The dosing above is community practice, not a regulator-validated protocol. Trial-validated dosing for NMN in humans does not exist for most use cases listed.
Risks and contraindications
Side effect profile at supplementation doses (250 to 500 mg/day) is mild: occasional GI upset, mild nausea, rare reports of headache. At higher doses (>1 gram/day) some users report flushing similar to niacin. Long-term safety beyond 12 to 18 months is uncharacterised in trials. The cancer-pathway concern is the same as for NAD+ generally: NAD+ is fuel for cellular metabolism including tumor cell metabolism, and SIRT1 activation (a downstream effect) cuts both ways depending on cancer type. Anyone with active or recent cancer should consult an oncologist before starting NMN. Pregnancy and breastfeeding off-limits by default. The FDA briefly blocked NMN's NDI status in 2022 (treating it as a drug-development article rather than a supplement) but supplement access was restored via court ruling in 2023; this is regulatory uncertainty worth knowing about even though it doesn't currently restrict access.
Where this stands legally
Sold as a dietary supplement under DSHEA (Dietary Supplement Health and Education Act). FDA briefly blocked the NDI status in 2022; supplement access was restored via court ruling in 2023. Brand examples: Tru Niagen, ProHealth, Renue By Science, Wonderfeel.
Sold as a food supplement under EU/UK supplement regulations. MHRA does not regulate as a medicine. Available through standard supplement retailers and online.
EU Novel Food regulation has not formally cleared NMN as of 2026; supplement sale operates in a grey zone in member states. EFSA has not made a definitive ruling.
TGA treats NMN as a complementary medicine when sold under therapeutic claims; supplement sale through standard channels is permitted.
Sold as a supplement through wellness retailers and longevity clinics. Bangkok longevity programmes commonly include NMN as part of a stack.
Available through supplement retailers under MOHAP supplement classification.
Where users say they source it
Names below are sourced from community discussion. None are currently scored against the Panya 11-signal rubric. Panya does not earn commission on any of these. You can search them yourself; treat the list as a starting point for your own diligence, not an endorsement.
- Tru NiagenPending Panya 11-signal audit
- Renue By SciencePending Panya 11-signal audit
- Wonderfeel (Nobel Prize-winner-affiliated brand)Pending Panya 11-signal audit
- ProHealth LongevityPending Panya 11-signal audit
- Bangkok longevity clinics (often bundle with broader stack)Pending Panya 11-signal audit
Full vendor scorecards for NMN land in a follow-up sprint after lawyer review and payment processor selection. We will not route users to any vendor that scores below 70 on the rubric.
Papers worth reading directly
- Yoshino et al. — Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 2021 →
- Igarashi et al. — Chronic nicotinamide mononucleotide supplementation elevates blood NAD+ levels and alters muscle function in healthy older men. NPJ Aging, 2022 →
- Mills et al. — Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab, 2016 →
- Rajman, Chwalek, Sinclair — Therapeutic Potential of NAD-Boosting Molecules. Cell Metab, 2018 →
Panya blog posts
The phrase on every grey-market peptide site. What it actually means, what it does not mean, and why reading it wrong costs people money.
The clinic route costs more and takes longer. The research-chem route puts more on you. Neither is wrong. Here is how to choose.
Adjacent reading
Track NMN in your peptide journal.
Panya users log their full stack at panya.health/journey. Public-by-default with per-entry privacy controls. Vote-validated by the community.